BRAINAURORA-B (06681) has announced that the Group has officially become a strategic partner of the Beijing Advanced Brain-Computer Interface Research Institute. On March 27, 2026, the Company's subsidiary, Zhejiang Brain Aurora Medical Technology Co., Ltd., signed a strategic cooperation agreement with the Institute. This partnership signifies a new phase of comprehensive transformation for brain-computer interface (BCI) technology. With BCI being designated a key development area in the national "16th Five-Year Plan" and related deployments in the 2026 Government Work Report, the BCI industry is entering a period of rapid growth. The establishment of the Beijing Advanced Brain-Computer Interface Research Institute marks a shift towards a new stage driven by deep clinical needs and systematic, full-chain transformation in China's BCI field. The Institute aims to address the urgent needs of over 100 million patients with neurological disorders in China, tackling the structural imbalance where technology advancement outpaces practical application scenarios. Collaborative innovation integrating industry, academia, research, and medicine is seen as an essential path forward. Medical rehabilitation has been identified as a core application area for BCI technology. Leveraging the top-tier clinical resources of Xuanwu Hospital, Capital Medical University, the initiative seeks to build an innovative ecosystem that merges medicine with engineering and integrates academic and industrial efforts. This is considered a crucial pathway for promoting the clinical translation of BCI technology and establishing a complete chain from data to validation. As an established participant in China's digital therapeutics market for cognitive disorders, the Group possesses deep expertise in integrating neuroscience and AI technologies. The collaboration with the Institute is expected to strongly facilitate the clinical validation and industrial application of core technologies. The two parties will engage in deep cooperation across several areas, leveraging the Institute's six common support platforms. These areas include the development of a multimodal neurological disease database, the creation of large-scale neuro-electrophysiological models, and the clinical validation of related BCI products. The Group will utilize its technical expertise and product development capabilities in the cognitive disorder digital therapeutics sector. By deeply integrating with the Institute's scientific research and clinical resources, the partnership aims to build a complete innovation chain from data and algorithms to validation and products, accelerating the clinical translation process for BCI technology. The Group's responsibilities include utilizing its technological advantages in digital therapeutics and artificial intelligence to participate in joint research and development of key areas such as large-scale neuro-electrophysiological models. It will also promote the product transformation and application validation of related technologies based on clinical needs, and collaborate with the Institute and clinical organizations to explore innovative application models for BCI technology in the diagnosis and treatment of cognitive disorders. The Institute's responsibilities involve providing cutting-edge research support and clinical resources in the BCI field. It will organize and conduct clinical research and validation studies through Xuanwu Hospital and a multi-center network, and establish common technology platforms to provide infrastructure support for cooperative R&D, including data, algorithms, and validation capabilities. Both parties have agreed to jointly advance the research, development, and clinical validation of key products in the BCI field. The Group will collaborate with the Institute and other strategic partners to promote joint R&D in key directions such as multimodal neurological disease databases, large-scale neuro-electrophysiological models, and closed-loop neuromodulation BCI products. This effort aims to construct an innovative ecosystem that bridges medicine and engineering and integrates academia with industry. The Board of Directors believes this strategic cooperation aligns with the Group's long-term development strategy. It will help the Group fully utilize top clinical resources to deepen its technological expertise and product portfolio in the BCI and cognitive disorder sectors. Through complementary strengths with the Institute, the Group is poised to further consolidate its leading position in the industry and create long-term value for shareholders.
Comments